GIMER Medical Highlighted by Microsoft’s VP of Healthcare in Taiwan’s National Innovation Award Demo Day
Sharon Fan, GIMER Medical’s Vice President of Strategy & Business Development, demonstrated the pain relief system StimOn on Taiwan’s National Innovation Award Demo Day. (GIMER Medical)
(Taipei, Taiwan; Dec. 19, 2022) Gimer Medical, the world's premier ultra-high frequency stimulation device manufacturer, was nominated as one of four scale-up companies to pitch on Taiwan’s National Innovation Award Demo Day. The event on Dec. 3 attracts more than 1,000 investors and medical professionals. GIMER was especially highlighted by Dr. David Rhew, Microsoft’s Global Chief Medical Officer & VP of Healthcare, as the company’s pain relief technology “could lead to a big opportunity down the road".
As a major event of both National Innovation Award and Healthcare+ Expo Taiwan 2022, the Demo Day gathers the country’s top medical professionals and venture capitals to encounter potential business opportunities. Microsoft’s Dr. David Rhew shares his positive impression on GIMER’s pain relief technology, commenting it “could lead to a big opportunity down the road" while explaining his judging criteria in a pre-recorded video. The two other judges - Harry Yang, President of the Medical Devices Products Group of Qisda; William Hung, Chief Investment Officer of Foxconn Technology also designate their questions to this pain solution focused scale-up.
Microsoft’s Global Chief Medical Officer & VP of Healthcare, Dr. David Rhew, highlighted GIMER Medical as its pain relief technology “could lead to a big opportunity down the road".
Almost ten years since establishment, GIMER Medical successfully completed its spinal cord stimulation system and built up the first ever implantable medical electronics supply chain in Taiwan. Through the cooperation of global partners like healthcare giant Medtronic, the company grew up from only five co-founders to a team with more than fifty staffs today. In August, 2022, its spinal cord stimulation system was granted US FDA’s IDE approval, while the American marketing clearance of its pain relief system StimOn was also obtained soon after.
StimOn, GIMER’s pain relief system which received US FDA’s marketing clearance in August, is estimated to be in the market in 2023. (GIMER Medical)
“We have come a long way with product research and development; the application or clinical trials also takes a huge amount of funding and resources. We are glad to be nominated to present our progress. I hope this opens the door to more opportunities in the future,” said Sharon Fan, the VP of Strategy & Business Development of GIMER Medical, who took out GIMER’s pain relief system StimOn from her pocket while presenting on stage. This tiny device is smaller than an earbud case and which will be GIMER’s first product to the market in 2023.
For the following moves, GIMER Medical will not only focus on its ultra-high frequency device development but to be able to provide various kinds of help to pain patients. The company will show up in the Consumer Electronics Show (CES) from Jan. 5th to 8th, 2023 to meet with international buyers in Las Vegas.
About GIMER Medical
GIMER Medical is a Taiwan based neuromodulation system provider focused on pulsed radiofrequency stimulation therapy. With the mission to provide long-lasting pain relief solutions for people living with chronic pain, the company has designed multiple systems built on its patented pulsed radiofrequency technology “+RF”. To support its mission further, GIMER has also established a subsidiary specializing in research, design, and contract manufacturing of implantable devices.
Media Contact
Shih-Yuan CHUEH (PR Manager) sy.chueh@gimermed.com；+886-2-2697-2680 #8225
